DE69731659D1 - Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv) - Google Patents

Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv)

Info

Publication number
DE69731659D1
DE69731659D1 DE69731659T DE69731659T DE69731659D1 DE 69731659 D1 DE69731659 D1 DE 69731659D1 DE 69731659 T DE69731659 T DE 69731659T DE 69731659 T DE69731659 T DE 69731659T DE 69731659 D1 DE69731659 D1 DE 69731659D1
Authority
DE
Germany
Prior art keywords
protein
virus
rsv
respiratory
synergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731659T
Other languages
English (en)
Other versions
DE69731659T2 (de
DE69731659T3 (de
Inventor
George A Cates
Sonia E Sanhueza
Raymond P Oomen
Michel H Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24725423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69731659(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur Ltd filed Critical Aventis Pasteur Ltd
Publication of DE69731659D1 publication Critical patent/DE69731659D1/de
Publication of DE69731659T2 publication Critical patent/DE69731659T2/de
Application granted granted Critical
Publication of DE69731659T3 publication Critical patent/DE69731659T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
DE69731659T 1996-07-12 1997-07-11 Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv) Expired - Lifetime DE69731659T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/679,060 US6020182A (en) 1996-07-12 1996-07-12 Subunit respiratory syncytial virus vaccine preparation
US679060 1996-07-12
PCT/CA1997/000497 WO1998002457A1 (en) 1996-07-12 1997-07-11 Subunit respiratory syncytial virus vaccine preparation

Publications (3)

Publication Number Publication Date
DE69731659D1 true DE69731659D1 (de) 2004-12-23
DE69731659T2 DE69731659T2 (de) 2006-03-02
DE69731659T3 DE69731659T3 (de) 2009-06-18

Family

ID=24725423

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0942928T Pending DE942928T1 (de) 1996-07-12 1997-07-11 Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv)
DE69731659T Expired - Lifetime DE69731659T3 (de) 1996-07-12 1997-07-11 Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE0942928T Pending DE942928T1 (de) 1996-07-12 1997-07-11 Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv)

Country Status (15)

Country Link
US (2) US6020182A (de)
EP (2) EP1477494A1 (de)
JP (1) JP2000501418A (de)
CN (1) CN1145639C (de)
AT (1) ATE282633T1 (de)
AU (1) AU716378B2 (de)
BR (1) BR9712970A (de)
CA (1) CA2259594C (de)
DE (2) DE942928T1 (de)
ES (1) ES2141065T5 (de)
GR (1) GR990300042T1 (de)
HK (1) HK1022704A1 (de)
NZ (1) NZ334115A (de)
RU (1) RU2243234C2 (de)
WO (1) WO1998002457A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation
US6017694A (en) * 1997-12-19 2000-01-25 American Cyanamid Company Methods of screening for modulators of respiratory syncytial virus matrix protein interaction
CA2355270A1 (en) * 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
WO2001006429A1 (en) * 1999-07-15 2001-01-25 Shea Robert S Method of sequencing chronic disease testing, reporting and evaluation
EP1255560B1 (de) * 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
FR2806912B1 (fr) * 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
WO2002009749A2 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Respiratory syncytial virus vaccine
US20040052800A1 (en) * 2000-08-07 2004-03-18 Bruce Carpick Stabilization of immunogens derived from paramyxoviruses
DE60136381D1 (de) * 2000-10-18 2008-12-11 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US7118888B2 (en) 2001-09-28 2006-10-10 University Of South Florida Board Of Trustees Gene expression vaccine
AU2002350342A1 (en) * 2001-12-20 2003-07-09 Aventis Pasteur Limited Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus
CA2484251C (en) 2002-04-30 2015-06-23 University Of South Florida Materials and methods for inhibition of respiratory syncytial virus infection
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
CA2518924C (en) * 2003-03-18 2016-06-07 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
US7736648B2 (en) * 2007-10-25 2010-06-15 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
WO2010077717A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
HUE035773T2 (en) * 2009-06-05 2018-05-28 Ablynx Nv Trivalent human airway giant cell virus (hrsv) nanotubes for preventing and / or treating respiratory infections
EP3988115A3 (de) * 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
AU2009353693B2 (en) * 2009-10-06 2016-07-21 Medimmune Ltd RSV-specific binding molecule
RU2612154C2 (ru) * 2009-12-23 2017-03-02 Санофи Пастер Способ культивирования адгезионных клеток
CN102199198A (zh) * 2011-03-28 2011-09-28 北京交通大学 人呼吸道合胞病毒f蛋白的纯化方法
KR20220119527A (ko) 2012-08-01 2022-08-29 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
CN112851766A (zh) * 2013-03-13 2021-05-28 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
WO2015084838A1 (en) * 2013-12-02 2015-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus g protein fragments
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU605476B2 (en) * 1986-01-14 1991-01-17 University Of North Carolina, The Vaccines for human respiratory virus
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US5723130A (en) * 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation

Also Published As

Publication number Publication date
EP0942928B2 (de) 2008-08-13
CN1230197A (zh) 1999-09-29
RU2243234C2 (ru) 2004-12-27
ES2141065T3 (es) 2005-05-01
WO1998002457A1 (en) 1998-01-22
ATE282633T1 (de) 2004-12-15
EP0942928A1 (de) 1999-09-22
GR990300042T1 (en) 2000-01-31
EP1477494A1 (de) 2004-11-17
EP0942928B1 (de) 2004-11-17
CA2259594C (en) 2003-11-11
DE69731659T2 (de) 2006-03-02
CA2259594A1 (en) 1998-01-22
JP2000501418A (ja) 2000-02-08
US6020182A (en) 2000-02-01
DE942928T1 (de) 2000-03-02
HK1022704A1 (en) 2000-08-18
AU716378B2 (en) 2000-02-24
CN1145639C (zh) 2004-04-14
ES2141065T1 (es) 2000-03-16
AU3431197A (en) 1998-02-09
ES2141065T5 (es) 2009-02-16
BR9712970A (pt) 2001-08-28
US6309649B1 (en) 2001-10-30
DE69731659T3 (de) 2009-06-18
NZ334115A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
DE69731659D1 (de) Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv)
DK1382348T3 (da) Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom
DE69637914D1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
DE3856141T2 (de) Respiratorisches syncytiales virus, impstoffe
IS7658A (is) Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
BR9506047A (pt) Partículas montadas de um virus de planta vacina para proteção contra patógenos humanos ou animais vacina de virus de animal fragmento de cdna de proteína de revestimento de cpmv vetor transcrito de rna e processo para proteger animais (incluíndo humanos) contra patógenos
PL352201A1 (en) Porcine circovirus vaccine in recombinant poxvirus
ES2110097T3 (es) Sistema de liberacion basado en proteinas.
DK162883A (da) N-glucosylerede carboxylsyreamidderivater, fremgangsmaade til fremstilling heraf samt deres anvendelse til paavirkning af organismens egen forsvarsmekanisme
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
ATE371373T1 (de) Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
CA2399172A1 (en) Cold-adapted equine influenza viruses
AU9215101A (en) Vaccines containing ribavirin and methods of use thereof
DK0551077T3 (da) Anvendelse af humant atrialt natriuretisk peptid til fremstilling af farmaceutiske præparater til behandling af akut lungeb
DE69323921T2 (de) Mutante des Respiratory-syncytial-Virus (RS-Virus) und eine eine solche Mutante enthaltende pharmazeutische Zusammensetzung
CA2302833A1 (en) Peptides derived from the attachment (g) protein of respiratory syncytial virus
WO2003022878A3 (en) Subunit respiratory syncytial virus vaccine preparation
WO1999014345A3 (de) Arzneimittel zur therapie einer manifesten lyme-borreliose
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
WO2002009749A3 (en) Respiratory syncytial virus vaccine
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
PL353349A1 (en) Method for isolating and purifying grass pollen allergens

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI PASTEUR LTD., TORONTO, ONTARIO, CA

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC